• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/10/21 8:55:45 AM ET
    $PAIC
    Business Services
    Finance
    Get the next $PAIC alert in real time by email
    SC 13G 1 formsc13g.htm FORM SC 13G Polar Asset Management Partners Inc.: Form SC 13G - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

    Petra Acquisition, Inc.

    (Name of Issuer)
      

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
       

    716421102

    (CUSIP Number)
       

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     [X]  Rule 13d-1(b)

     [_]  Rule 13d-1(c)

     [_]  Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No.  716421102

    13G

    Page 2 of 5 Pages


    1

    Names of Reporting Persons

    Polar Asset Management Partners Inc.

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  [ ]
    (b)  [ ]

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

    Canada

    Number of Shares Beneficially Owned by Each Reporting Person With:

     

    5

    Sole Voting Power

    700,000

    6

    Shared Voting Power

     

    7

    Sole Dispositive Power

    700,000

    8

    Shared Dispositive Power

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

    700,000

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    [ ]

    11

    Percent of class represented by amount in row (9)

    7.53%

    12

    Type of Reporting Person (See Instructions)

    IA

           

    Page 2 of 5


    CUSIP No.  716421102

    13G

    Page 3 of 5 Pages

    Item 1. 

    (a) Name of Issuer:

     The name of the issuer is Petra Acquisition, Inc. (the "Company").

    (b) Address of Issuer's Principal Executive Offices:

    The Company's principal executive offices are located at 5 West 21st Street, New York, New York 10010.

    Item 2. 

    (a) Name of Person Filing:

    This statement is filed by Polar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada, which serves as the investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company ("PMSMF") with respect to the Shares (as defined below) directly held by PMSMF.

    (b) Address of Principal Business Office or, if None, Residence: 

    The address of the business office of the Reporting Person is 401 Bay Street, Suite 1900, PO Box 19, Toronto, Ontario M5H 2Y4, Canada.

    (c) Citizenship:

    The citizenship of the Reporting Person is Canada.

    (d) Title and Class of Securities:

    Common Stock, par value $0.001 per share (the "Shares").

    (e) CUSIP No.:

    716421102

    Item 3.  If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [_] Broker or dealer registered under Section 15 of the Act;

    (b) [_] Bank as defined in Section 3(a)(6) of the Act;

    (c) [_] Insurance company as defined in Section 3(a)(19) of the Act;

    (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940;

    (e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

    (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

    Page 3 of 5


    CUSIP No.  716421102

    13G

    Page 4 of 5 Pages

    (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

    (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

    (j) [X] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

    (k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:                                                                                    

    The Reporting Person is an investment fund manager, portfolio manager, exempt market dealer and commodity trading manager registered with the Ontario Securities Commission.

    Item 4. Ownership

    The percentages used herein are calculated based upon 9,290,651 Shares outstanding as of November 16, 2020 as disclosed in the Company's Quarterly Report on Form 10-Q for the quarterly period ended  September 30, 2020, filed with the Securities and Exchange Commission on November 16, 2020.

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for the Reporting Person and is incorporated herein by reference.

    Item 5. Ownership of Five Percent or Less of a Class.

    Not applicable.

    Item 6. Ownership of more than Five Percent on Behalf of Another Person.

    See Item 2. PMSMF has the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of more than 5% of the Shares.

    Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable.

    Item 8. Identification and classification of members of the group.

    Not applicable.

    Page 4 of 5


    CUSIP No.  716421102

    13G

    Page 5 of 5 Pages

    Item 9. Notice of Dissolution of Group.

     Not applicable.

    Item 10. Certifications.

    By signing below the Reporting Person certifies that, to the best of its knowledge and belief, (i) the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect and (ii) the foreign regulatory schemes applicable to investment fund managers and broker-dealers are substantially comparable to the regulatory schemes applicable to the functionally equivalent U.S. institutions. The Reporting Person also undertakes to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 10, 2021

    POLAR ASSET MANAGEMENT PARTNERS INC.

    /s/ Andrew Ma 
    Name:  Andrew Ma
    Title:  Chief Compliance Officer

    Page 5 of 5


    Get the next $PAIC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

    - Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today it has received approval from the Federal Agency for Medicines and Health Products (FAMHP) and the local Committee of Medical Ethics in Belgium to conduct a Phase 2b influenza viral challenge study. The Phase 2b, randomized, double-blind, influenza viral challenge study (RV

    9/28/21 9:00:00 AM ET
    $PAIC
    Business Services
    Finance

    Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

    Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m

    8/30/21 6:00:00 AM ET
    $PAIC
    Business Services
    Finance

    PETRA ACQUISITION, INC. RECEIVES EXPECTED NASDAQ NOTIFICATION REGARDING DELAYED FORM 10-Q

    New York, NY, June 01, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ:PAIC) (the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced that on May 28, 2021, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") advising that because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"). Nasdaq has inform

    6/1/21 4:30:00 PM ET
    $PAIC
    Business Services
    Finance

    $PAIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Feis Lawrence disposed of $7,465,890 worth of shares (731,950 units at $10.20)

    4 - Petra Acquisition Inc. (0001810560) (Issuer)

    1/11/22 3:59:54 PM ET
    $PAIC
    Business Services
    Finance

    SEC Form 3: New insider Feis Lawrence claimed ownership of 746,491 shares

    3 - Petra Acquisition Inc. (0001810560) (Issuer)

    11/2/21 2:39:14 PM ET
    $PAIC
    Business Services
    Finance

    SEC Form 4: Glazer Capital, Llc sold $6,597,824 worth of Common stock (654,546 units at $10.08)

    4 - Petra Acquisition Inc. (0001810560) (Issuer)

    9/23/21 4:21:06 PM ET
    $PAIC
    Business Services
    Finance

    $PAIC
    SEC Filings

    View All

    Petra Acquisition, Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    1/14/22 4:28:56 PM ET
    $PAIC
    Business Services
    Finance

    Petra Acquisition, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    1/13/22 3:53:16 PM ET
    $PAIC
    Business Services
    Finance

    Petra Acquisition, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    1/12/22 4:49:37 PM ET
    $PAIC
    Business Services
    Finance

    $PAIC
    Financials

    Live finance-specific insights

    View All

    Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

    Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m

    8/30/21 6:00:00 AM ET
    $PAIC
    Business Services
    Finance

    $PAIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

    SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

    1/11/22 3:34:57 PM ET
    $PAIC
    Business Services
    Finance

    SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

    SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

    10/12/21 4:02:40 PM ET
    $PAIC
    Business Services
    Finance

    SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

    SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

    10/12/21 10:33:03 AM ET
    $PAIC
    Business Services
    Finance